Portal de Periódicos da CAPES

Scientific Opinion on the substantiation of a health claim related to caffeine and increased alertness pursuant to Article 13(5) of Regulation (EC) No 1924/2006

2014; Wiley; Volume: 12; Issue: 2 Linguagem: Inglês

10.2903/j.efsa.2014.3574

1831-4732

Obesity, Physical Activity, Diet

EFSA JournalVolume 12, Issue 2 3574 OpinionOpen Access Scientific Opinion on the substantiation of a health claim related to caffeine and increased alertness pursuant to Article 13(5) of Regulation (EC) No 1924/2006 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)Search for more papers by this author EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)Search for more papers by this author First published: 20 February 2014 https://doi.org/10.2903/j.efsa.2014.3574Citations: 1 Panel members: Carlo Agostoni, Roberto Berni Canani, Susan Fairweather-Tait, Marina Heinonen, Hannu Korhonen, Sébastien La Vieille, Rosangela Marchelli, Ambroise Martin, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna Nowicka, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Sean (J.J.) Strain, Inge Tetens, Daniel Tomé, Dominique Turck and Hans Verhagen Correspondence: [email protected] Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims: Carlo Agostoni, Susan Fairweather-Tait, Marina Heinonen, Ambroise Martin, Hildegard Przyrembel, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Sean (J.J.) Strain, Inge Tetens, Hendrik Van Loveren, Hans Verhagen and Peter Willatts for the preparatory work on this scientific opinion. Adoption date: 5 February 2014 Published date: 20 February 2014 Question number: EFSA-Q-2013-00399 On request from: Competent Authority of United Kingdom following an application by SmithKline Beecham Limited AboutPDF ToolsExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract Following an application from SmithKline Beecham Limited, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of United Kingdom, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to caffeine and increased alertness. The food constituent, caffeine, which is the subject of the health claim, is sufficiently characterised. Increased alertness might be a beneficial physiological effect. A claim on caffeine and increased alertness, in the general adult population, for products containing at least 75 mg of caffeine per serving, has already been assessed by the Panel with a favourable outcome. In the present application, the applicant proposed that, in order to bear the claim, a product should contain at least 40 mg of caffeine per serving. In weighing the evidence, the Panel took into account that most studies which measured reaction time in various cognitive tasks found no effect of caffeine at doses < 75 mg. In the particular dose range between 40 and < 75 mg, no effect of caffeine was found on the majority of outcome measures of reaction time. The Panel notes that the majority of studies with caffeine doses of 75 mg or higher showed a significant reduction in measures of reaction time. On the basis of the evidence provided, the Panel reiterates its previous conclusion that, in order to bear the claim, a product should contain at least 75 mg caffeine per serving. The Panel concludes that a cause and effect relationship has not been established between the consumption of caffeine and increased alertness under the conditions of use proposed by the applicant. References Arnaud MJ, 1985. Comparative metabolic disposition of [1-Me14C]caffeine in rats, mice, and Chinese hamsters. Drug Metabolism and Disposition, 13, 471– 478. Arnaud MJ, 2011. Pharmacokinetics and metabolism of natural methylxanthines in animal and man. Handb Exp Pharmacol, 33– 91. Blanchard J and Sawers SJ, 1983. The absolute bioavailability of caffeine in man. European Journal of Clinical Pharmacology, 24, 93– 98. Bonati M, Latini R, Galletti F, Young JF, Tognoni G and Garattini S, 1982. Caffeine disposition after oral doses. Clinical Pharmacology and Therapeutics, 32, 98– 106. Botton PH, Costa MS, Ardais AP, Mioranzza S, Souza DO, da Rocha JB and Porciuncula LO, 2010. Caffeine prevents disruption of memory consolidation in the inhibitory avoidance and novel object recognition tasks by scopolamine in adult mice. Behavioural Brain Research, 214, 254– 259. Bunker ML and McWilliams M, 1979. Caffeine content of common beverages. Journal of the American Dietetic Association, 74, 28– 32. Costa MS, Botton PH, Mioranzza S, Ardais AP, Moreira JD, Souza DO and Porciuncula LO, 2008. Caffeine improves adult mice performance in the object recognition task and increases BDNF and TrkB independent on phospho-CREB immunocontent in the hippocampus. Neurochemistry International, 53, 89– 94. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011. Scientific Opinion on the substantiation of health claims related to caffeine and increased fat oxidation leading to a reduction in body fat mass (ID 735, 1484), increased energy expenditure leading to a reduction in body weight (ID 1487), increased alertness (ID 736, 1101, 1187, 1485, 1491, 2063, 2103) and increased attention (ID 736, 1485, 1491, 2375) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 EFSA Journal 2011; 9(4):2054, 29 pp. doi:10.2903/j.efsa.2011.2054 El Yacoubi M, Ledent C, Menard JF, Parmentier M, Costentin J and Vaugeois JM, 2000. The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. British Journal of Pharmacology, 129, 1465– 1473. Fredholm BB, Battig K, Holmen J, Nehlig A and Zvartau EE, 1999. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacological Reviews, 51, 83– 133. Fredholm BB, Irenius E, Kull B and Schulte G, 2001. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochemical Pharmacology, 61, 443– 448. Griffiths RR, Evans SM, Heishman SJ, Preston KL, Sannerud CA, Wolf B and Woodson PP, 1990. Low-dose caffeine discrimination in humans. Journal of Pharmacology and Experimental Therapeutics, 252, 970– 978. Haskell C and Kennedy D, 2011a, unpublished. The time course of acute effects of three doses of caffeine on attention, motor speed and mood. Report No. RHS00944. Brain, Performance and Nutrition Research Centre, School of Psychology and Sport Science, Northumbria University, Newcastle upon Tyne, UK. 36 pp. Haskell C and Kennedy D, 2011b, unpublished. The acute cognitive effects of four low doses of caffeine. Report No. RHS01267. Brain, Performance and Nutrition Research Centre, School of Life Sciences, Northumbria University, Newcastle upon Tyne, UK. 41 pp. Hewlett P and Smith A, 2007. Effects of repeated doses of caffeine on performance and alertness: new data and secondary analyses. Hum Psychopharmacol, 22, 339– 350. Kuznicki JT and Turner LS, 1986. The effects of caffeine on caffeine users and non-users. Physiology and Behavior, 37, 397– 408. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G and Parmentier M, 1997. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature, 388, 674– 678. Lelo A, Miners JO, Robson RA and Birkett DJ, 1986. Quantitative assessment of caffeine partial clearances in man. British Journal of Clinical Pharmacology, 22, 183– 186. Lieberman HR, Wurtman RJ, Emde GG, Roberts C and Coviella IL, 1987a. The effects of low doses of caffeine on human performance and mood. Psychopharmacology, 92, 308– 312. Lieberman HR, Wurtman RJ, Emde GG and Coviella IL, 1987b. The effects of caffeine and aspirin on mood and performance. J Clin Psychopharmacol, 7, 315– 320. Liguori A, Hughes JR and Grass JA, 1997. Absorption and subjective effects of caffeine from coffee, cola and capsules. Pharmacology, Biochemistry and Behavior, 58, 721– 726. Liu ZW and Gao XB, 2007. Adenosine inhibits activity of hypocretin/orexin neurons by the A1 receptor in the lateral hypothalamus: a possible sleep-promoting effect. Journal of Neurophysiology, 97, 837– 848. Lowe M, 2012, unpublished. Pooled Analysis of 4 Studies Investigating the Effects of Caffeine on Cognitive Functions: Study Report, Appendix and Statistical Analysis Plan., 78 pp. Magkos F and Kavouras SA, 2005. Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action. Critical Reviews in Food Science and Nutrition, 45, 535– 562. Marks V and Kelly JF, 1973. Absorption of caffeine from tea, coffee, and coca cola. Lancet, 1, 827. Mumford GK, Evans SM, Kaminski BJ, Preston KL, Sannerud CA, Silverman K and Griffiths RR, 1994. Discriminative stimulus and subjective effects of theobromine and caffeine in humans. Psychopharmacology, 115, 1– 8. Nehlig A, Daval JL and Debry G, 1992. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Research. Brain Research Reviews, 17, 139– 170. Newton R, Broughton LJ, Lind MJ, Morrison PJ, Rogers HJ and Bradbrook ID, 1981. Plasma and salivary pharmacokinetics of caffeine in man. European Journal of Clinical Pharmacology, 21, 45– 52. Okada M, Mizuno K and Kaneko S, 1996. Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. Neuroscience Letters, 212, 53– 56. Perera V, Gross AS, Xu H and McLachlan AJ, 2011. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. Journal of Pharmacy and Pharmacology, 63, 1161– 1168. Rogers PJ, 2011, unpublished. Caffeine speed of action study: An investigation into the time course of action of the effects of caffeine on alertness and performance. Report RHS00794. School of Experimental Psychology, University of Bristol, UK 21 pp. Rogers PJ and Dernoncourt C, 1998. Regular caffeine consumption: a balance of adverse and beneficial effects for mood and psychomotor performance. Pharmacol Biochem Behav, 59, 1039– 1045. Schiffmann SN, Libert F, Vassart G and Vanderhaeghen JJ, 1991. Distribution of adenosine A2 receptor mRNA in the human brain. Neuroscience Letters, 130, 177– 181. Seng KY, Fun CY, Law YL, Lim WM, Fan W and Lim CL, 2009. Population pharmacokinetics of caffeine in healthy male adults using mixed-effects models. Journal of Clinical Pharmacy and Therapeutics, 34, 103– 114. Seng KY, Teo WL, Fun CY, Law YL and Lim CL, 2010. Interrelations between plasma caffeine concentrations and neurobehavioural effects in healthy volunteers: model analysis using NONMEM. Biopharmaceutics and Drug Disposition, 31, 316– 330. Silverman K and Griffiths RR, 1992. Low-dose caffeine discrimination and self-reported mood effects in normal volunteers. Journal of the Experimental Analysis of Behavior, 57, 91– 107. Smit HJ and Rogers PJ, 2000. Effects of low doses of caffeine on cognitive performance, mood and thirst in low and higher caffeine consumers. Psychopharmacology, 152, 167– 173. Smith A, 2009. Effects of caffeine in chewing gum on mood and attention. Human Psychopharmacology, 24, 239– 247. Smith A, Sturgess W and Gallacher J, 1999. Effects of a low dose of caffeine given in different drinks on mood and performance. Human Psychopharmacology: Clinical and Experimental, 14, 473– 482. Smith AP, Christopher G and Sutherland D, 2013. Acute effects of caffeine on attention: a comparison of non-consumers and withdrawn consumers. J Psychopharmacol, 27, 77– 83. Smith JE, Kyle LA and Rogers PJ, 2011, unpublished. Caffeine Speed of Action Study: An investigation of the speed of action of caffeine on alertness and performance. Study Report RHS01035. School of Experimental Psychology, University of Bristol, UK. 25 pp. Specterman M, Bhuiya A, Kuppuswamy A, Strutton PH, Catley M and Davey NJ, 2005. The effect of an energy drink containing glucose and caffeine on human corticospinal excitability. Physiology and Behavior, 83, 723– 728. Van Dongen HP, Price NJ, Mullington JM, Szuba MP, Kapoor SC and Dinges DF, 2001. Caffeine eliminates psychomotor vigilance deficits from sleep inertia. Sleep, 24, 813– 819. Wang Y and Lau CE, 1998. Caffeine has similar pharmacokinetics and behavioral effects via the i.p. and p.o. routes of administration. Pharmacology, Biochemistry and Behavior, 60, 271– 278. Wyatt JK, Cajochen C, Ritz-De Cecco A, Czeisler CA and Dijk DJ, 2004. Low-dose repeated caffeine administration for circadian-phase-dependent performance degradation during extended wakefulness. Sleep, 27, 374– 381. Yamato T, Yamasaki S, Misumi Y, Kino M, Obata T and Aomine M, 2002. Modulation of the stress response by coffee: an in vivo microdialysis study of hippocampal serotonin and dopamine levels in rat. Neuroscience Letters, 332, 87– 90. Yeomans MR, Ripley T, Davies LH, Rusted JM and Rogers PJ, 2002. Effects of caffeine on performance and mood depend on the level of caffeine abstinence. Psychopharmacology (Berl), 164, 241– 249. Citing Literature Volume12, Issue2February 20143574 ReferencesRelatedInformation